SRR934952
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.5742444152431
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.668
- TNFA_SIGNALING_VIA_NFKB+0.603
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.597
- IL6_JAK_STAT3_SIGNALING+0.582
- INTERFERON_GAMMA_RESPONSE+0.559
- ALLOGRAFT_REJECTION+0.555
- TGF_BETA_SIGNALING+0.550
- INTERFERON_ALPHA_RESPONSE+0.546
- IL2_STAT5_SIGNALING+0.515
- INFLAMMATORY_RESPONSE+0.498
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.434
- KRAS_SIGNALING_DN-0.431
- SPERMATOGENESIS-0.331
- OXIDATIVE_PHOSPHORYLATION-0.150
- HEDGEHOG_SIGNALING-0.079
- BILE_ACID_METABOLISM-0.012
- MYOGENESIS+0.028
- ESTROGEN_RESPONSE_EARLY+0.057
- PEROXISOME+0.068
- FATTY_ACID_METABOLISM+0.086
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934782 | — | — | 0.984 |
| 2 | SRR934750 | — | — | 0.978 |
| 3 | SRR934845 | — | — | 0.976 |
| 4 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.971 |
| 5 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.964 |
| 6 | SRR934829 | — | — | 0.961 |
| 7 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.960 |
| 8 | SRR934987 | — | — | 0.960 |
| 9 | SRR934816 | — | — | 0.959 |
| 10 | SRR934866 | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.668 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.603 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.597 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.582 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.559 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.555 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.546 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.515 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.498 | Idelalisib | — uncovered |
| APOPTOSIS | 0.486 | Idelalisib | — uncovered |
| COAGULATION | 0.465 | Binimetinib | — uncovered |
| COMPLEMENT | 0.463 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.402 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.382 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.378 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.374 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.364 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.358 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.347 | Inavolisib | — uncovered |